For finishing of this type of the discussion I offer to review the following old publications (from classical - Haffner SM, Lehto S, Ronnemaa T, et al. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 1998; 339: 229–234., and following - DOI: 10.1111/j.1365-2796.1997.tb00006.x: DOI: 10.1056/NEJM199807233390404:doi: 10.1016/j.acvd.2010.11.013. Epub 2011 Mar 26.; DOI: 10.1007/5584_2020_481 etc. ) and then review the results of the recent trials especial with with two new classes of the antidiabetic drugs (DOI: 10.1093/eurjpc/zwac132; DOI: 10.1177/1479164120941809; doi: 10.1016/j.ijcard.2020.08.021.; doi: 10.1111/dom.14074.; doi: 10.1016/j.molmet.2020.101102. etc.)
After reviewing even only resume of the indicated publication summary you will find the the first answer for your question and could find more deep info. The modern antidiabetic drugs dramatically changed the modern concepts of the treatment. And we are still studying these effects.